Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.

about

Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases.Prevalence of Non-Cytochrome P450-Mediated Metabolism in Food and Drug Administration-Approved Oral and Intravenous Drugs: 2006-2015.

P2860

Q36353657-49D12C72-0BC2-4933-94B1-98E7B44EBCF5 Q38880368-D3C53CF6-3FF1-4E52-AFCC-73CA57A5EE6C

P2860

Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.

Item

http://www.wikidata.org/entity/Q41008169

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.

@en

type

Item

label

Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.

@en

prefLabel

Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.

@en

P1476

Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.

@en

P2093

Wei Li

http://www.w3.org/2001/XMLSchema#string

Yafei Xing

http://www.w3.org/2001/XMLSchema#string

Yong Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study

Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.

The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.

Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.

P2888

s00280-015-2753-4

P304

1253-1260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-015-2753-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1009484031

http://www.w3.org/2001/XMLSchema#string

P698

25917289

http://www.w3.org/2001/XMLSchema#string

P921

7-ethyl-10-hydroxycamptothecin

Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.

about

P2860

P2860

Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921